Tofacitinib in Juvenile Idiopathic Arthritis

N/ANot Yet RecruitingNCT07211932

Consorci Sanitari de l'Alt Penedès i Garraf58 enrolled

Overview

This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Juvenile Idiopathic Arthritis (JIA)

Interventions

TofacitinibDRUG

Patients received tofacitinib for the treatment of juvenile idiopathic arthritis (JIA).

Eligibility

Sex: ALLMax age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: Diagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist. Documentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA. Age under 18 years at the time of the treatment indication with tofacitinib. Exclusion criteria: Participants diagnosed with any of the following conditions: Reactive arthritis Arthritis associated with inflammatory bowel disease Arthritis associated with another autoimmune disease

Locations (3)

Hospital Sant Joan de Déu Barcelona

Barcelona, Barcelona, Spain

Corporació Sanitària Parc Taulí de Sabadell

Sabadell, Barcelona, Spain

Hospital de Vilafranca

Vilafranca del Penedès, Barceona, Spain

Outcomes

Primary Outcomes

JADAS-10

Change in the Juvenile Arthritis Disease Activity Score (JADAS-10) score at 12 months of treatment with tofacitinib. Range score: 0 to 10, the less score the better

Time frame: Baseline and 12 months

Central Contacts

Noemí Casaponsa

CONTACT

+34938960025 recerca@csapg.cat

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.